Literature DB >> 32651247

Performance validity test failure in clinical populations-a systematic review.

Laura McWhirter1, Craig W Ritchie2, Jon Stone2, Alan Carson2.   

Abstract

Performance validity tests (PVTs) are widely used in attempts to quantify effort and/or detect negative response bias during neuropsychological testing. However, it can be challenging to interpret the meaning of poor PVT performance in a clinical context. Compensation-seeking populations predominate in the PVT literature. We aimed to establish base rates of PVT failure in clinical populations without known external motivation to underperform. We searched MEDLINE, EMBASE and PsycINFO for studies reporting PVT failure rates in adults with defined clinical diagnoses, excluding studies of active or veteran military personnel, forensic populations or studies of participants known to be litigating or seeking disability benefits. Results were summarised by diagnostic group and implications discussed. Our review identified 69 studies, and 45 different PVTs or indices, in clinical populations with intellectual disability, degenerative brain disease, brain injury, psychiatric disorders, functional disorders and epilepsy. Various pass/fail cut-off scores were described. PVT failure was common in all clinical groups described, with failure rates for some groups and tests exceeding 25%. PVT failure is common across a range of clinical conditions, even in the absence of obvious incentive to underperform. Failure rates are no higher in functional disorders than in other clinical conditions. As PVT failure indicates invalidity of other attempted neuropsychological tests, the finding of frequent and unexpected failure in a range of clinical conditions raises important questions about the degree of objectivity afforded to neuropsychological tests in clinical practice and research. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cognition; neuropsychiatry; neuropsychology

Year:  2020        PMID: 32651247     DOI: 10.1136/jnnp-2020-323776

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  7 in total

Review 1.  Posttraumatic functional movement disorders and litigation.

Authors:  P Santens; A Bruggeman
Journal:  Acta Neurol Belg       Date:  2021-03-27       Impact factor: 2.396

2.  Radiation dose to circumscribed brain regions and neurocognitive function in patients with meningioma.

Authors:  Angela Sekely; Derek S Tsang; Donald Mabbott; Paul Kongkham; Gelareh Zadeh; Konstantine K Zakzanis; Kim Edelstein
Journal:  Neurooncol Pract       Date:  2022-02-19

Review 3.  Functional neurological disorder: new subtypes and shared mechanisms.

Authors:  Mark Hallett; Selma Aybek; Barbara A Dworetzky; Laura McWhirter; Jeffrey P Staab; Jon Stone
Journal:  Lancet Neurol       Date:  2022-04-14       Impact factor: 59.935

4.  Long-term neurocognitive, psychological, and return to work outcomes in meningioma patients.

Authors:  Angela Sekely; Konstantine K Zakzanis; Donald Mabbott; Derek S Tsang; Paul Kongkham; Gelareh Zadeh; Kim Edelstein
Journal:  Support Care Cancer       Date:  2022-01-18       Impact factor: 3.359

Review 5.  A broader perspective: Functional symptoms beyond Neurology.

Authors:  S Benbadis; R Ledford; T Sawchuk; B Dworetzky
Journal:  Epilepsy Behav Rep       Date:  2021-11-25

Review 6.  Symptom and Performance Validity Assessment in European Countries: an Update.

Authors:  Thomas Merten; Brechje Dandachi-FitzGerald; Vicki Hall; Thomas Bodner; Luciano Giromini; Johann Lehrner; Héctor González-Ordi; Pablo Santamaría; Ben Schmand; Giuseppe Di Stefano
Journal:  Psychol Inj Law       Date:  2021-11-24

7.  Performance validity in outpatients with multiple sclerosis and cognitive complaints.

Authors:  I M Nauta; D Bertens; M van Dam; M Huiskamp; S Driessen; Jjg Geurts; Bmj Uitdehaag; L Fasotti; H E Hulst; B A de Jong; M Klein
Journal:  Mult Scler       Date:  2021-07-02       Impact factor: 6.312

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.